Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy

Cancer Immunology, Immunotherapy

Volumn 54, Issue 9, 2005, Pages 815-825

  Lesinski, Gregory B ^a   Valentino, Daniel ^a   Hade, Erinn M ^b   Jones, Susie ^b   Magro, Cynthia ^b   Chaudhury, Abhik Ray ^b   Walker, Michael J ^b   Carson III, William E ^a,b,c  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Adjuvant therapy; Interferon alpha; Malignant melanoma; STAT1; STAT2

Indexed keywords

ALPHA2B INTERFERON; STAT1 PROTEIN; STAT2 PROTEIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; LUNG METASTASIS; LYMPH NODE; MALE; MELANOMA; PRIORITY JOURNAL; RECURRENT DISEASE; SKIN DEFECT; STAINING; SURVIVAL; TUMOR BIOPSY; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DNA-BINDING PROTEINS; FEMALE; HUMANS; INTERFERON-ALPHA; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; SURVIVAL RATE; TRANS-ACTIVATORS;

EID: 22244457944     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0649-y     Document Type: Article

References (30)

1. Badgwell B, Lesinski GB, Magro C, Abood G, Skaf A, Carson WE (2003) The anti-tumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line. J Surg Res 116:129
2. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM (2002) Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:119
3. Carson WE (1998) Interferon-alpha-induced activation of signal transducer and activator of transcription proteins in malignant melanoma. Clin Cancer Res 4:2219
4. Creagan ET, Dalton RJ, Ahmann DL, Jung SH, Morton RF, Langdon RM Jr, Kugler J, Rodrigue LJ (1995) Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 13:2776
5. Chawla-Sarkar M, Leaman DW, Jacobs BS, Tuthill RJ, Chatterjee-Kishore M, Stark GR, Borden EC (2002) Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (stat1). J Interferon Cytokine Res 22:603
6. Darnell JE Jr, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415
7. Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M (2004) Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 22:53
8. Haque SJ, Williams BR (1998) Signal transduction in the interferon system. Semin Oncol 25:14
9. Jackson DP, Watling D, Rogers NC, Banks RE, Kerr IM, Selby PJ, Patel PM (2003) The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line. Melanoma Res 13:219
10. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457
11. Kim SH, Cohen B, Novick D, Rubinstein M (1997) Mammalian type I interferon receptors consists of two subunits: IFNaR1 and IFNaR2. Gene 196:279
12. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH (2000) High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18:2444
13. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370
14. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U (2004) A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10:1670
15. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7
16. Kovarik J, Boudny V, Kocak I, Lauerova L, Fait V, Vagundova M (2003) Malignant melanoma associates with deficient IFN-induced STAT 1 phosphorylation. Int J Mol Med 12:335
17. Lens MB, Dawes M (2002) Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 20:1818
18. Leonard WJ, O'Shea JJ (1998) Jaks and STATs: biological implications. Annu Rev Immunol 16:293
19. Lesinski GB, Anghelina M, Zimmerer J, Bakalakos T, Badgwell B, Parihar R, Hu Y, Becknell B, Abood G, RayChaudhury A, Magro C, Durbin J, Carson WE (2003) The anti-tumor effects of interferon-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest 112:170
20. Lesinski GB, Kondadasula SV, Crespin T, Shen L, Kendra K, Walker MJ, Carson WE (2004) Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon alfa immunotherapy. J Natl Cancer Inst 96:1131
21. Levy DE, Gilliland DG (2000) Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene 19:2505
22. Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S, Beglinger C, Heim MH (2000) Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer 85:720
23. Rousseau DL Jr, Ross MI, Johnson MM, Prieto VG, Lee JE, Mansfield PF, Gershenwald JE (2003) Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 10:569
24. Schneeberger A, Koszik F, Stingl G (1995) Immunologic host defense in melanoma: delineation of effector mechanisms involved and of strategies for the augmentation of their efficacy. J Invest Dermatol 105:1108
25. Sun WH, Pabon C, Alsayed Y, Huang PP, Jandeska S, Uddin S, Platanias LC, Rosen ST (1998) Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood 91:570
26. Thompson JA (2002) The revised American Joint Committee on Cancer staging system for melanoma. Semin Oncol 29:361
27. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48
28. Wong LH, Hatzinisiriou I, Devenish RJ, Ralph SJ (1998) IFN-gamma priming up-regulates IFNstimulated gene factor 3 (ISGF3) components, augmenting responsiveness of IFNresistant melanoma cells to type I IFNs. J Immunol 160:5475
29. Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, Edmondson S, Devenish RJ, Ralph SJ (1997) Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 272:28779
30. Zhang YW, Wang LM, Jove R, Vande Woude GF (2002) Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 21:217